The Established Heavyweight: Tirz (The Dual Agonist)
For many in our community, Tirz has been the gold standard. As a dual agonist, it targets two primary metabolic pathways: the Glucagon-like peptide-1 (GLP-1) and the Glucose-dependent insulinotropic polypeptide (GIP) receptors.
This combination was a massive leap forward from the early “mono-therapy” peptides. By stimulating both receptors, researchers observed a synergistic effect that significantly Transformed glycemic control and appetite suppression. In clinical settings, the 15mg protocol has shown up to a 21% reduction in body weight over a 72-week period.
At WLA, we offer Tirz in various strengths to suit different research phases. It’s a reliable, well-documented compound that offers a stable foundation for those looking to Combat metabolic dysfunction with proven clinical outcomes.
Key Research Specs for Tirz:
- Classification: Dual GLP-1/GIP Receptor Agonist.
- Function: Enhances insulin secretion, delays gastric emptying, and induces early satiety.
- Physical Contents: Lyophilized powder in vacuum-sealed glass vials.
- Common Dosages: 5mg, 10mg, 15mg.
The Challenger: Ret (The “Triple Threat” Agonist)
Enter Ret. If Tirz is the heavyweight champion, Ret is the high-tech disruptor from the future. Retatrutide is what we call a “triple agonist.” It does everything Tirz does but adds a third, vital mechanism: the Glucagon receptor.
By targeting GLP-1, GIP, and Glucagon simultaneously, Ret targets the “holy trinity” of metabolic pathways. This isn’t just about eating less; it’s about Transforming how the body handles energy expenditure. While GLP-1 and GIP handle the intake side of the equation (satiety), the Glucagon component focuses on the output side: increasing thermogenesis and fat oxidation.
Early Phase 2 data suggests that Ret can lead to an incredible 24% weight reduction in just 48 weeks. That is a significantly faster trajectory than its dual-agonist predecessor. For researchers looking to push the boundaries of what’s possible in metabolic upregulation, our Retatrutide range offers unparalleled potential.
Key Research Specs for Ret:
- Classification: Triple GIP/GLP-1/GCG Receptor Agonist.
- Function: Appetite suppression + Glycemic control + Enhanced fat oxidation/thermogenesis.
- Physical Contents: High-purity lyophilized peptide.
- Available Strengths: 5mg, 10mg, 20mg, 30mg, 50mg.
